 |
蔣祖搴博士後研究員 Dr. Zu-Chian Chiang |
| E-mail： |
|
| Ext：15628 | |
|
學歷： |
|
|
專長: 功能性胜肽合成與應用(癌症 / 骨組織工程) |
經歷:
國際期刊-同儕評審
福建師範大學-南方生物醫學研究中心 博士後研究員
中央研究院生物化學研究所 博士後研究員
台灣大學/台大醫院 博士後研究員
國家衛生研究院 博士研究生
弘馳股份有限公司 助理工程師兼助理研究員
研究興趣：
功能性胜肽合成與應用(癌症 / 骨組織工程)
生物微分子-大分子複合材料開發（再生醫學）
抗體藥物複合體（ADCs）開發(癌症標靶治療)
特異性適配體（Aptamer）開發(癌症診斷和治療)
CAR-T 細胞設計與免疫檢查點耐藥克服
成果發表(5年內) Publication (in five years)：
|
1. |
Zu-Chian Chiang, Jizhen Lin*, Qi Chen*. Immune checkpoint co-expression combined with systemic inflammatory index: an innovative breakthrough in prognostic evaluation of lymphoma in Egypt. World Journal of Clinical Oncology, 2026, 117391 (Ready for Publishing Online). (JCR Q2) |
|
2. |
Shuchun Lin, Xiaohua Hu, Yunhai Gao, Zu-Chian Chiang* and Jizhen Lin*. Metabolic changes and immune escape of IL-34 in p53 mutated head and neck Cancers. Journal of Pharmacology and Drug Metabolism, 2026, 9: 1-12. (IF: 6.2) |
|
3. |
Jizhen Lin†, Qi Chen†, Sheng Yang†, Shuchun Lin and Zu-Chian Chiang*. The progress and prospects of B7-H3 targeted immunotherapy in the treatment of solid tumors: Multidimensional breakthrough from CAR-T cells to antibody drug conjugates. Journal of Pharmaceutics & Drug Development, 2026, 13(1): 101. (IF: 3.2) |
|
4. |
Zu-Chian Chiang and Xi Huang*. Genetic Insights into Coronary Heart Disease in the Teochew Population – Bridging Gaps in Precision Medicine. World Journal of Cardiology, 2026, 18(1): 113579. (JCR Q2) |
|
5. |
Sheng Yang#, Shuping Zheng#, Zhihua Feng#, Miaofang Lin, Min Liu*, Zu-Chian Chiang* and Qi Chen*. Structural Basis of the VapBC5 Complex from Mycobacterium abscessus and Its Role in Regulating Persister Cell Formation. International Journal of Biological Macromolecules, 2026, 349: 150860. (JCR Q1) |
|
6. |
Qiong Zhang#, Zu-Chian Chiang#,*, Huanjiao Weng#, Xinyi Chen, Ningning Zhao, Cailin Yan, Yonglei Xiao, Jizhen Lin* & Yunlu Xu*. Enhancement of B7-H3 chimeric antigen receptor-T cell efficacy via the coexistence effect of IL-7, IL-15 and CCL19 for pancreatic and lung xenograft tumors. Biochemical Pharmacology, 2026, 245: 117673. (JCR Q1) |
|
7. |
Zu-Chian Chiang*, Shan Xu, Xiangqian Zhao, Min Liu*, Jizhen Lin* and Qi Chen*. Generation and characterization of 7DC-DM1: a non-cleavable CD47-targeting antibody-drug conjugates with antitumor effects. International Journal of Biological Macromolecules, 2025, 310: 142844. (JCR Q1) |
|
8. |
Qing Liu#, Zu-Chian Chiang#,*, Xiangxian Zhao, Dong-Ya Cui, Xinxin Li, Hao Chen, Fangyu Lin, Tao Jiang, Qi Chen*, Xiaoyan Lin* and Jizhen Lin*. Strengthening effect of thalidomide combined with anti-PD1 antibody on enhancing immunity for lung cancer therapy. Current Pharmaceutical Biotechnology, 2025, 26(17): 1-11. (JCR Q3) |
| 9. | Jizhen Lin#, Qi Chen#, Xiaohua Hu and Zu-Chian Chiang*. 7DC-DM1 and Beyond: Redefining Payload Delivery Strategies in Next-Generation Antibody-Drug Conjugates. Clinics of Oncology, 2025, 9(5): 1-5. (IF: 3.567) |
| 10. | Zu-Chian Chiang, Shubin Fang#, Yang-kun Shen, Dongya Cui, Huanjiao Weng, Dawei Wang, Yuxiang Zhao, Jizhen Lin* and Qi Chen*. Development of Novel CD47-Specifific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo. Frontiers in Oncology, 2022, 12: 1-14. (JCR Q2) |
| 11. | Zu-Chian Chiang, Yi-Kai Chiu, Cheng-Chung Lee, Yueh-Liang Tsou, Hong-Sen Chen, Horng-Ru Hsu, Tzung-Jie Yang, An-Suei Yang, and Andrew H.-J. Wang*. Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells. PLOS ONE, 2020, 15(9): 1-15. (JCR Q1) |